Can a little known drug in AstraZeneca's pipeline make a comeback as a PARP add-on? Yale scientists explain how
AstraZeneca’s cediranib may not have made the cut as a single agent to treat ovarian cancer, but Yale researchers think it could serve as a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
